Greg Lindsey - Voyageur Pharmaceuticals Director
| VM Stock | CAD 0.05 0.01 9.09% |
Director
Mr. Greg Lindsey is Chief Financial Officer, Corporationrationrate Secretary, Director of Golden Sun Capital Inc. Mr. Lindsey was a Partner with Gowling Lefleur Henderson LLP since 2010 and is currently the leader of the Calgary tax practice. Prior to 2010, Mr. Lindsey was a Partner with Felesky Flynn LLP since 2005. Mr. Lindsey holds a Bachelor of Laws from the University of Victoria and a Bachelor of Commerce from the Queen University. Mr. Lindsey also has held the designation of Chartered Accountant since 1997.
| Age | 39 |
| Address | 4103B Center Street, Calgary, AB, Canada, T2E 2Y6 |
| Phone | 587 779 6166 |
| Web | https://voyageurpharmaceuticals.ca |
Voyageur Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.359) % which means that it has lost $0.359 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.965) %, meaning that it created substantial loss on money invested by shareholders. Voyageur Pharmaceuticals' management efficiency ratios could be used to measure how well Voyageur Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.08 in 2024. Return On Capital Employed is likely to drop to -0.08 in 2024. At this time, Voyageur Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to climb to about 2.3 M in 2024, whereas Other Assets are likely to drop 0.86 in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Andrea Rosen | Element Fleet Management | 64 | |
| Rocco Colella | Element Fleet Management | N/A | |
| Mary Webster | Stella Jones | 65 | |
| Paul Damp | Element Fleet Management | 63 | |
| Alexander Greene | Element Fleet Management | 60 | |
| Harold Bridge | Element Fleet Management | 71 | |
| John Shineton | Stella Jones | N/A | |
| Simon Pelletier | Stella Jones | 52 | |
| James Manzi | Stella Jones | 69 | |
| Marc Poulin | Richelieu Hardware | 52 | |
| Joan LammTennant | Element Fleet Management | 66 | |
| Donald Chatterley | Winpak | N/A | |
| Andrew Clarke | Element Fleet Management | 48 | |
| Martti AarnioWihuri | Winpak | N/A | |
| Carol Goldman | ECN Capital Corp | 61 | |
| Daniel Picotte | Stella Jones | 62 | |
| Alan Martyszenko | Winpak | N/A | |
| Richard Venn | Element Fleet Management | 65 | |
| Gordon Giffin | Element Fleet Management | 65 | |
| Rubin McDougal | Element Fleet Management | 62 | |
| Nycol PageauGoyette | Stella Jones | 73 | |
Management Performance
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.36 |
Voyageur Pharmaceuticals Leadership Team
Elected by the shareholders, the Voyageur Pharmaceuticals' board of directors comprises two types of representatives: Voyageur Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Voyageur. The board's role is to monitor Voyageur Pharmaceuticals' management team and ensure that shareholders' interests are well served. Voyageur Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Voyageur Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Merle Olson, Director | ||
| Randy Henkle, Director | ||
| Brent Willis, Chief Executive Officer, Director | ||
| Albert Deslauriers, Chief Officer | ||
| Evatt Merchant, Independent Director | ||
| Brent BscEng, CEO President | ||
| Joseph Campo, Independent Director | ||
| Christopher Wolfenberg, President CEO, Director | ||
| Greg Lindsey, Chief Financial Officer, Corporate Secretary, Director | ||
| Bradley PEng, COO Founder | ||
| Pierre Magnan, Independent Director | ||
| Trent Abraham, Director |
Voyageur Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Voyageur Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 6.97 M | ||||
| Shares Outstanding | 138.81 M | ||||
| Shares Owned By Insiders | 10.21 % | ||||
| Number Of Shares Shorted | 9.54 K | ||||
| Price To Book | 6.28 X | ||||
| EBITDA | (1.34 M) | ||||
| Net Income | (1.4 M) | ||||
| Cash And Equivalents | 27.59 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Voyageur Stock analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |